BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/1/2014 8:25:00 PM | Browse: 1034 | Download: 1317
 |
Received |
|
2014-01-24 08:35 |
 |
Peer-Review Started |
|
2014-01-24 14:26 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2014-04-29 13:08 |
 |
Revised |
|
2014-05-12 20:15 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2014-06-26 17:03 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2014-06-26 17:24 |
 |
Articles in Press |
|
2014-06-26 17:52 |
 |
Edit the Manuscript by Language Editor |
|
2014-07-14 16:27 |
 |
Typeset the Manuscript |
|
2014-09-16 19:58 |
 |
Publish the Manuscript Online |
|
2014-10-01 20:25 |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Study |
| Article Title |
Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wei Rao, Man Xie, Tao Yang, Jian-Jun Zhang, Wei Gao, Yong-Lin Deng, Hong Zheng, Cheng Pan, Yi-He Liu and Zhong-Yang Shen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High-tech R&D Program of China (863 Program) |
2012AA021001 |
|
| Corresponding Author |
Zhong-Yang Shen, MD, PhD, Department of Organ Transplantation, Tianjin Key Laboratory of Organ Transplantation, Tianjin First Central Hospital, Fukang Road 24, Tianjin 300192, China. shenzhongyangmd@126.com |
| Key Words |
Pediatric liver donor liver transplantation; Occult hepatitis B infection; De novo hepatitis B infection |
| Core Tip |
We reported our experience of de novo hepatitis B virus (HBV) infection after pediatric living donor liver transplantation (LDLT), which showed that the incidence of de novo HBV infection in pediatric LDLT was 16.7% in our center. Among hepatitis B core antibody (HBcAb)-positive allografts, 43.7% were intrahepatic HBV DNA positive. Positive intrahepatic HBV DNA in allografts was predictive of de novo HBV infection after LDLT in children who were given HBcAb-positive allografts. Hepatitis B surface antibody/HBcAb positivity exhibited weak effectiveness in preventing children receiving HBcAb-positive allografts from de novo HBV infection. Lamivudine prophylaxis therapy is essential to prevent de novo HBV infection in pediatric patients from HBcAb-positive allografts with positive intrahepatic HBV DNA. |
| Publish Date |
2014-10-01 20:25 |
| Citation |
Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol 2014; 20(36): 13159-13166 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i36/13159.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i36.13159 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.